Altered muscarinic acetylcholine receptor (mAChR) activity is implicated in many disorders including Alzheimer's disease, schizophrenia, pain, obesity and diabetes, but lack of knowledge of the precise functional roles of the individual mAChR subtypes has hampered drug development. Wess and colleagues review recent insights gained frommAChR-knockout mice that are helping to address this issue and discuss the therapeutic potential of subtype-selective mAChR modulation.
- Jürgen Wess
- Richard M. Eglen
- Dinesh Gautam